Xiong Lai, Wang Feng, Qi Xie Xiao
Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China.
J BUON. 2019 Mar-Apr;24(2):424-430.
Gliomas are tumors with high incidence and poor prognosis among primary brain tumors and they present difficulties in surgical removal, having also high recurrence rate. The efficacy of various treatments on high-grade gliomas is not satisfactory. Some studies have found that age, surgery, radiotherapy, chemotherapy and other factors, such as tumor molecular pathology, have a certain impact on the recurrence of high-grade gliomas, and a common concern in the studies of high-grade gliomas is that one single treatment often has low efficacy. However, with the development of molecular biology, there is a deeper understanding of the pathogenesis of these tumors, and molecular targeted therapy has attracked impressive attention. The treatment of recurrent high-grade gliomas is also more abundant , Diversity of treatment options than before. Oncolytic virus therapy, stem cell therapy, immunotherapy and electric field therapy are now available. These emerging treatments are expected to improve the prospect of treating recurrent high-grade gliomas.
胶质瘤是原发性脑肿瘤中发病率高且预后差的肿瘤,它们在手术切除方面存在困难,复发率也很高。各种治疗方法对高级别胶质瘤的疗效并不令人满意。一些研究发现,年龄、手术、放疗、化疗以及肿瘤分子病理学等其他因素对高级别胶质瘤的复发有一定影响,而高级别胶质瘤研究中的一个共同关注点是单一治疗往往疗效较低。然而,随着分子生物学的发展,对这些肿瘤的发病机制有了更深入的了解,分子靶向治疗引起了广泛关注。复发性高级别胶质瘤的治疗方法也比以前更加丰富,治疗选择更加多样。溶瘤病毒疗法、干细胞疗法、免疫疗法和电场疗法现在都已出现。这些新兴治疗方法有望改善复发性高级别胶质瘤的治疗前景。